Denali Advisors LLC Has $477,000 Holdings in Embecta Corp. $EMBC

Denali Advisors LLC decreased its holdings in shares of Embecta Corp. (NASDAQ:EMBC) by 14.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,226 shares of the company’s stock after selling 8,200 shares during the quarter. Denali Advisors LLC’s holdings in Embecta were worth $477,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of EMBC. Exchange Traded Concepts LLC grew its position in shares of Embecta by 1,261.1% during the 1st quarter. Exchange Traded Concepts LLC now owns 7,391 shares of the company’s stock worth $94,000 after buying an additional 6,848 shares during the period. Oppenheimer Asset Management Inc. grew its position in shares of Embecta by 9.0% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 11,004 shares of the company’s stock worth $140,000 after buying an additional 907 shares during the period. Wealthquest Corp acquired a new stake in shares of Embecta during the 1st quarter worth approximately $48,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Embecta during the 1st quarter worth approximately $154,000. Finally, Teacher Retirement System of Texas grew its position in shares of Embecta by 64.3% during the 1st quarter. Teacher Retirement System of Texas now owns 91,525 shares of the company’s stock worth $1,167,000 after buying an additional 35,817 shares during the period. Institutional investors and hedge funds own 93.83% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on EMBC. Zacks Research cut shares of Embecta from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 7th. Wall Street Zen upgraded shares of Embecta from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a research note on Wednesday, October 8th. Mizuho reduced their price objective on shares of Embecta from $13.00 to $12.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 16th. Finally, BTIG Research reissued a “buy” rating and set a $25.00 price objective on shares of Embecta in a research note on Friday, September 5th. One investment analyst has rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $19.00.

Embecta Price Performance

Embecta stock opened at $14.25 on Thursday. The company’s 50 day simple moving average is $14.28 and its 200 day simple moving average is $12.15. Embecta Corp. has a fifty-two week low of $9.20 and a fifty-two week high of $21.48. The firm has a market capitalization of $833.48 million, a price-to-earnings ratio of 9.97, a PEG ratio of 0.79 and a beta of 1.10.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Friday, August 8th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.35. The business had revenue of $295.50 million for the quarter, compared to analyst estimates of $278.15 million. Embecta had a net margin of 7.58% and a negative return on equity of 23.40%. Embecta’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.74 EPS. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. As a group, analysts predict that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, September 15th. Stockholders of record on Friday, August 29th were issued a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 4.2%. The ex-dividend date was Friday, August 29th. Embecta’s dividend payout ratio is 41.96%.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.